B O O K - American College of Rheumatology

monday
Upon completion of this session, participants should be able to:
• define the diagnostics criteria for juvenile fibromyalgia
• state the prevalence and rates of disability due to this health
condition
• describe the suspected etiology of this health condition
• define the role of family members in the management of
juvenile fibromyalgia
• explain interventions used to treat juvenile fibromyalgia
B310
Osteoporosis Treatment Update C PS
Moderator: Kori A. Dewing, MN, ARNP; VA Mason Medical
Center; Everett, WA
Speaker: Julie L. Carkin, MD; The Seattle Arthritis Clinic; Seattle,
WA
Session Overview:
Rheumatology nurse practitioners, physician assistants and
other health care team members serve a critical role in
diagnosing and managing patients with osteoporosis. There is
much debate about who should be treated and for how long.
Therefore, it is important for rheumatology health care providers
to be knowledgeable of the evidence-based data to ensure that
treatment decisions are implemented to best meet the goal of
fracture prevention.
Upon completion of this session, participants should be able to:
• identify the clinical risk factors with bone mineral density to
more accurately identify fracture risk
• describe the scientific data supporting length of osteoprorsis
treatment
• define the rationale for continuing or discontinuing
osteoporosis therapy
B308
Rehabilitation in the Age of Biologics C PS
Moderator: Mary Wright, BS, OT; The Toledo Hospital; Toledo,
OH
Speakers: Kamala M. Nola, PharmD, MS; Lipscomb College of
Pharmacy; Nashville, TN
Maura D. Iversen, PT, DPT, SD, MPH; Northeastern University;
Boston, MA
Session Overview:
There has been a national decline in referrals to occupational
and physical therapy since the introduction of biologic therapies
for the treatment of rheumatic diseases. As a result, patients
are missing access to information to help with the management
of their disease. Exercise, joint protection and activities of
daily living ideas are examples of what are missing from the
management of their disease.
Upon completion of this session, participants should be able to:
• cite the development and progression of the biologic
medications
• distinguish the different classes of biologics and how they
treat the rheumatic diseases
• describe the different methods of how these medications are
administered
• identify appropriate therapy treatments for patients on
biologic medications
• describe to physicians how therapy can complement the
medical treatment for maximum positive outcomes of the
patient
• explain to patients how therapy can help minimize problems
associated with the diseases these medications treat
B311
Reproductive and Sexual Health Issues for Women
with Rheumatic Disease c/r
Moderator: Susan M. Oliver, RN MSc; Pennine Musculoskeletal
Partnership; Oldham, United Kingdom
Speakers: Wendy Marder, MD; University of Michigan; Ann
Arbor, MI
W. Tracy Talmadge, PhD; Atlanta, GA
Senait Fisseha, MD, JD; University of Michigan; Ann Arbor, MI
Session Overview:
Among wom en with autoimmune disease, issues relating to
premature ovarian failure, reproductive viability and general
sexual health often get overlooked due to underlying severe
disease activity or lack of awareness on the part of the health
care provider. Autoimmune disease often affects women during
their reproductive years, and the consequences of therapies
administered during this time have larger implications that will
impact them throughout their lives. It is important for health
care providers to be aware of methods to preserve fertility
among these patients and the burden of disease associated
with premature ovarian failure and be prepared to discuss the
options with patients.
Upon completion of this session, participants should be able to:
• describe the epidemiology, comorbidities, and public
health burden of premature ovarian failure in patients
with systemic disease exposed to gonadotoxic agents (e.g.,
cyclophosphamide)
• identify sexual health implications and management strategies
for patients with early menopause and/or infertility
• explain the emerging options for ovarian protection and
fertility preservation and assess the pros and cons
REF Industry Roundtable-
Supported Symposia
6:30 - 9:30 PM
The REF would like to thank the industry leaders that have made
a significant multi-year commitment to the REF for participation
in the Industry Roundtable.
In appreciation for their commitment, these industry leaders
have been invited to host a symposium during the annual
meeting. In 2010, there are two types of symposia offered to
attendees: CME-accredited and non-CME accredited. For CMEaccredited
symposia, the sponsoring organization is responsible
for planning and providing CME credit. The non-CME accredited
symposia have been planned and will be implemented in
accordance with the requirements of the FDA and applicable
standards of the PhRMA Code on Interactions with Healthcare
Professionals. Please visit the organization’s exhibit booth, the
industry-supported symposia booth or see page 280 for more
information.
54
2010 Program Book